These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 3114812)

  • 1. Intravenous physostigmine treatment of Alzheimer's disease evaluated by psychometric testing, regional cerebral blood flow (rCBF) measurement, and EEG.
    Gustafson L; Edvinsson L; Dahlgren N; Hagberg B; Risberg J; Rosén I; Fernö H
    Psychopharmacology (Berl); 1987; 93(1):31-5. PubMed ID: 3114812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physostigmine and tetrahydroaminoacridine treatment of Alzheimer's disease.
    Gustafson L
    Acta Neurol Scand Suppl; 1993; 149(Rand):39-41. PubMed ID: 8128836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebral pharmacodynamics of physostigmine in Alzheimer's disease investigated using single-photon computerised tomography.
    Hunter R; Wyper DJ; Patterson J; Hansen MT; Goodwin GM
    Br J Psychiatry; 1991 Mar; 158():351-7. PubMed ID: 2036533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of central cholinergic stimulation on regional cerebral blood flow in Alzheimer's disease.
    Wilson K; Bowen D; Francis P; Tyrrell P
    Br J Psychiatry; 1991 Apr; 158():558-62. PubMed ID: 2054572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physostigmine in Alzheimer's disease: effects on cognitive functioning, cerebral glucose metabolism analyzed by positron emission tomography and cerebral blood flow analyzed by single photon emission tomography.
    Tune L; Brandt J; Frost JJ; Harris G; Mayberg H; Steele C; Burns A; Sapp J; Folstein MF; Wagner HN
    Acta Psychiatr Scand Suppl; 1991; 366():61-5. PubMed ID: 1897377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type: a double-blind placebo-controlled trial.
    Jenike MA; Albert MS; Heller H; Gunther J; Goff D
    J Clin Psychiatry; 1990 Jan; 51(1):3-7. PubMed ID: 2403997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological and neuropsychological characterization of physostigmine responders and nonresponders in Alzheimer's disease.
    Harrell LE; Jope RS; Falgout J; Callaway R; Avery C; Spiers M; Leli D; Morere D; Halsey JH
    J Am Geriatr Soc; 1990 Feb; 38(2):113-22. PubMed ID: 2405043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L-deprenyl and physostigmine for the treatment of Alzheimer's disease.
    Marin DB; Bierer LM; Lawlor BA; Ryan TM; Jacobson R; Schmeidler J; Mohs RC; Davis KL
    Psychiatry Res; 1995 Oct; 58(3):181-9. PubMed ID: 8570774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group.
    van Dyck CH; Newhouse P; Falk WE; Mattes JA
    Arch Gen Psychiatry; 2000 Feb; 57(2):157-64. PubMed ID: 10665618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group.
    Thal LJ; Schwartz G; Sano M; Weiner M; Knopman D; Harrell L; Bodenheimer S; Rossor M; Philpot M; Schor J; Goldberg A
    Neurology; 1996 Dec; 47(6):1389-95. PubMed ID: 8960716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Alzheimer disease by continuous intravenous infusion of physostigmine.
    Asthana S; Raffaele KC; Berardi A; Greig NH; Haxby JV; Schapiro MB; Soncrant TT
    Alzheimer Dis Assoc Disord; 1995; 9(4):223-32. PubMed ID: 8749612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
    Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine.
    Davis KL; Mohs RC
    Am J Psychiatry; 1982 Nov; 139(11):1421-4. PubMed ID: 6753611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia.
    Christie JE; Shering A; Ferguson J; Glen AI
    Br J Psychiatry; 1981 Jan; 138():46-50. PubMed ID: 7023592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physostigmine effects in Alzheimer's disease: relationship to dementia severity.
    Schwartz AS; Kohlstaedt EV
    Life Sci; 1986 Mar; 38(11):1021-8. PubMed ID: 3512944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical studies of the cholinergic deficit in Alzheimer's disease. II. Psychopharmacologic studies.
    Mohs RC; Davis BM; Greenwald BS; Mathé AA; Johns CA; Horvath TB; Davis KL
    J Am Geriatr Soc; 1985 Nov; 33(11):749-57. PubMed ID: 2865282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of oral physostigmine in Alzheimer's disease.
    Stern Y; Sano M; Mayeux R
    Ann Neurol; 1987 Sep; 22(3):306-10. PubMed ID: 3674795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral tetrahydroaminoacridine treatment of Alzheimer's disease evaluated clinically and by regional cerebral blood flow and EEG.
    Minthon L; Gustafson L; Dalfelt G; Hagberg B; Nilsson K; Risberg J; Rosén I; Seiving B; Wendt PE
    Dementia; 1993; 4(1):32-42. PubMed ID: 8358504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term administration of oral physostigmine in Alzheimer's disease.
    Stern Y; Sano M; Mayeux R
    Neurology; 1988 Dec; 38(12):1837-41. PubMed ID: 3057398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease.
    Thal LJ; Masur DM; Blau AD; Fuld PA; Klauber MR
    J Am Geriatr Soc; 1989 Jan; 37(1):42-8. PubMed ID: 2642499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.